恆瑞醫藥(01276.HK)向Glenmark授予瑞康曲妥珠單抗開發及商業化許可
恆瑞醫藥(01276.HK)宣佈與印度製藥公司Glenmark Pharmaceuticals旗下Glenmark Specialty達成協議,將向其授出瑞康曲妥珠單抗在除中國大陸、香港、澳門及臺灣地區、美國、加拿大、歐洲、日本、俄羅斯、亞美尼亞、阿塞拜疆、白俄羅斯、哈薩克斯坦、吉爾吉斯斯坦、摩爾多瓦、塔吉克斯坦、土庫曼斯坦和烏茲別克斯坦以外的全球範圍內,開發及商業化的獨家權利有償許可。
恆瑞醫藥將會獲得首付款1,800萬美元,並有資格獲取高達10.93億美元的與註冊及銷售相關里程碑付款,以及銷售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.